Match!
Cancer Chemotherapy and Pharmacology
IF
3.01
Papers
8524
Papers 8484
1 page of 849 pages (8,484 results)
Newest
#1Ken Ogasawara (BMS: Bristol-Myers Squibb)H-Index: 15
#2Patricia LoRusso (Yale Cancer Center)H-Index: 60
Last. Gopal Krishna (BMS: Bristol-Myers Squibb)H-Index: 1
view all 8 authors...
PURPOSE Fedratinib, an oral selective kinase inhibitor with activity against both wild type and mutationally activated Janus kinase 2, has been approved for the treatment of adult patients with intermediate-2 or high-risk myelofibrosis by the US Food and Drug Administration. In vitro studies indicated that fedratinib was an inhibitor of several cytochrome P450 (CYP) enzymes. The primary objective of this study was to evaluate the effects of repeated doses of fedratinib on the activity of CYP2D6,...
Source
#1G. NoguchiH-Index: 2
#2Noboru Nakaigawa (YCU: Yokohama City University)H-Index: 24
Last. Kimito OsakaH-Index: 5
view all 17 authors...
Nivolumab is part of the standard therapy for mRCC. Although deep and long-lasting responses are seen in some patients, the benefit of treatment is limited to some patients and the majority of patients will experience disease progression. PD-L1 is still under evaluation as a predictive biomarker and there is an urgent need to establish biomarkers for the treatment of nivolumab. Here, we investigate C-reactive protein (CRP) at 1 month after treatment of nivolumab as a target to predict the respon...
Source
#1T. Tsukioki (Okayama University)
#2Tadahiko Shien (Okayama University)H-Index: 14
Last. Hirokuni Ikeda (Okayama University)H-Index: 7
view all 13 authors...
Metformin has been suggested to possibly reduce cancer risk. However, the mechanism underlying the positive effects of metformin on cancer treatment remains unclear. We conducted a prospective study to evaluate the effects of preoperative metformin in patients with early breast cancer. We evaluated the effects on immunological factors (TILs, CD4 + , CD8 + , PD-L1, IFNγ and IL-2) by comparing core needle biopsies (CNB) obtained before metformin treatment with surgical specimens. Seventeen patient...
Source
#1Yanjiao Yi (Academy of Medical Sciences, United Kingdom)
#2Zining Liu (Academy of Medical Sciences, United Kingdom)
Last. Bao Song (Academy of Medical Sciences, United Kingdom)H-Index: 5
view all 10 authors...
Doublet combination chemotherapy is commonly considered a second-line treatment for advanced non-small cell lung cancer (NSCLC) in China. This multi-institutional retrospective analysis evaluated and compared the efficacy between combination and mono-therapy after platinum-based first-line chemotherapy in Chinese patients with advanced NSCLC. We retrospectively reviewed 335 patients who received second-line chemotherapy for advanced NSCLC. The primary endpoint was overall survival (OS), and the ...
Source
#1Xandra García-González (Hospital General Universitario Gregorio Marañón)H-Index: 4
#2Bartosz Kaczmarczyk (Hospital General Universitario Gregorio Marañón)
Last. María Sanjurjo-Sáez (Hospital General Universitario Gregorio Marañón)H-Index: 10
view all 11 authors...
Several clinical guidelines recommend genetic screening of DPYD, including coverage of the variants c.1905 + 1G>A(DPYD*2A), c.1679T>G(DPYD*13), c.2846A>T, and c.1129-5923C>G, before initiating treatment with fluoropyrimidines. However, this screening is often inadequate at predicting the occurrence of severe fluoropyrimidine-induced toxicity in patients. Using a complementary approach combining whole DPYD exome sequencing and in silico and structural analysis, as well as phenotyping of DPD by me...
Source
#1Yongxia Zhu (Zhengzhou University)
#2Zhihao Liu (Sichuan University)H-Index: 4
Last. Luoting Yu (Sichuan University)H-Index: 16
view all 11 authors...
PURPOSE Polo-like kinase 4 (PLK4), a member of the polo-like kinase family, plays several important roles in mitotic regulation, including centrosome duplication, spindle formation, and cytokinesis. PLK4 overexpression is frequently detected in many human cancers, including ovarian cancer, and the inhibition of PLK4 activity results in cancer cell mitotic arrest and apoptosis. Therefore, PLK4 might be a valid therapeutic target for antitumor therapy. In the present study, we aimed to determine i...
Source
PURPOSE Mercaptopurine (6MP) is essential to cure childhood acute lymphoblastic leukemia (ALL). A liquid 6MP formulation was recently introduced to facilitate oral 6MP administration, especially to children. Its approval and bioequivalence with 6MP tablet were based on comparative pharmacokinetics in 60 healthy adults. Due to potential pharmacokinetic differences between healthy adults and children with ALL, we compared pharmacokinetics of tablet and liquid 6MP formulations in children with ALL....
Source
#1Kathleen Dekeister (UCBL: Claude Bernard University Lyon 1)
Last. R. Osborne (Sunnybrook Health Sciences Centre)H-Index: 5
view all 13 authors...
PURPOSE In a low-risk gestational trophoblastic neoplasia (GTN) treated with methotrexate (MTX), the modeled hCG (human chorionic gonadotropin) residual concentration (hCGres), calculated with NONMEM program® (NM) during the first 50 treatment days, is a predictor of MTX-resistance risk. This model was implemented with another algorithm on https://www.biomarker-kinetics.org/hCG. The objective was to confirm the validity of the website estimations with respect to NM. METHODS The consistencies of ...
Source
#1Lenka N. C. Boyd (VU: VU University Amsterdam)
#2Godefridus J. Peters (VU: VU University Amsterdam)H-Index: 40
Last. Elisa Giovannetti (VU: VU University Amsterdam)H-Index: 39
view all 4 authors...
In preclinical models of biliary tract cancer, NUC-1031 showed less potency than gemcitabine, no correlation with potential biomarkers and only moderate additive interaction in combination with cisplatin. These findings should prompt further careful pharmacological and translational studies to better define the purported therapeutic advantage of NUC-1031 over gemcitabine. That would be a more cautious approach than the phase III clinical trial which is planning to enrol 828 patients with biliary...
Source
#1Jeerawan Klangjorhor (CMU: Chiang Mai University)H-Index: 5
#2Areerak Phanphaisarn (CMU: Chiang Mai University)H-Index: 3
Last. Dumnoensun Pruksakorn (CMU: Chiang Mai University)H-Index: 8
view all 8 authors...
PURPOSE Early prediction of clinical response to conventional chemotherapy is a significant factor in determining an overall treatment strategy for osteosarcoma. METHODS Cells were extracted from treatment-naive biopsies from 16 osteosarcoma patients who received a doxorubicin and cisplatin-based neoadjuvant chemotherapy regimen and their sensitivities to doxorubicin and cisplatin were measured as IC50 values. Associations of in vitro drug sensitivity (IDS) levels and clinical outcomes were exam...
Source
12345678910
Top fields of study
Pharmacokinetics
Cancer
Chemotherapy
Medicine
Pharmacology